CTOS 2016

Randomized Phase 3, Multicenter, Open-Label Study Comparing Evofosfamide (EVO) in Combination with Doxorubicin (D) versus D Alone in Patients with Advanced Soft-Tissue Sarcoma (STS): Study TH-CR-406/SARC021

CTOS 2016

This randomized phase 3 study compared the efficacy and safety of evofosfamide (EVO) plus doxorubicin (D) with D alone in patients with locally advanced unresectable or metastatic STS previously untreated with chemotherapy for advanced disease. Patients on EVO+D could receive [ Read More ]

Trabectedin Combined with Nivolumab in Advanced STS

CTOS 2016

The combination of trabectedin and anti–PD-1 therapy may synergistically attack tumor cells and promote antitumor immunity. This pilot feasibility study was conducted to assess the safety, toxicity, and efficacy of this combination in patients with advanced soft-tissue sarcoma (STS). Each [ Read More ]